Therapeutic Targeting Of Tight Junctions In Intestinal Disorders

Therapeutic Targeting of Tight Junctions in Intestinal Disorders

Beth Israel Deaconess Medical Center (BIDMC)

Claudin 18.2 as an emerging target in gastrointestinal cancers

Targeting CLDN18.2 with zolbetuximab in gastric and GEJ cancer

Dr Robert Silverman, Gut Brain Axis in Health and Disease

Impact of Zolbetuximab on Gastric Cancer Treatment

GI Oncology Now

Tight control and treat to target: How to assess the effectiveness of therapy

Intestinal Epithelial Function – 2018 Refresher Course Pt 2

American Physiological Society

Claudin 18.2: a biomarker for gastric cancer

Is Leaky Gut Causing All Of Your Problems?!? (The Advanced Intestinal Barrier Assessment)

Precision Point Diagnostics

SPOTLIGHT: zolbetuximab and m-FOLFOX6 in CLDN18.2+, HER2- GEJ cancer

LB1908: a novel CAR-T cell therapy targeting claudin 18.2 in GI malignancies

Mesothelioma biology: key genes and therapeutic targeting

Tight Junction

Leaky Gut and You I MBBCH

The Network Nurse

Targeted therapies for gastroesophageal adenocarcinoma

Immunology in the Gut Mucosa

How can I drastically improve gut health?

Doctor Mike Hansen

17 Principles of Targeted Therapy

Hope For Stomach Cancer

The Role of Inflammation in Mental Disorders with Andrew H. Miller, MD | MGC Ep. 82

Emeran Mayer, MD

The Connections: Nitric Oxide, Methylation, and the Microbiome in Illness